Azenta, Inc. (AZTA) FY2025 10-K Annual Report
Azenta, Inc. (AZTA) 10-K annual report for fiscal year 2025, filed with SEC EDGAR on Dec 4, 2025. This page provides AI-powered analysis including business overview, management discussion & analysis (MD&A), risk factors, and key financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE) extracted from XBRL.
Azenta, Inc. FY2025 10-K Analysis
Business Overview
- • Core business model centered on life sciences sample management and genomic services technology relying on intellectual property rights
- • Increased focus on managing risks from expiring patents starting 2025 through 2044, risking increased competition
Management Discussion & Analysis
- • Revenue details and YoY change not disclosed in provided MD&A excerpt
- • Profitability or margin figures not included in provided text
Risk Factors
- • Regulatory risk from potential misuse of synthetic gene products under genetic engineering restrictions narrowing gene synthesis markets
- • Geopolitical risk from US-China trade tensions and increased sales exposure to China (39% of revenue outside North America, growing China operations)
Azenta, Inc. FY2025 Key Financial MetricsXBRL
Revenue
$594M
▼ -9.5% YoY
Net Income
-$56M
▲ +66.0% YoY
Gross Margin
45.5%
▲ +539bp YoY
Operating Margin
-4.5%
▲ +2606bp YoY
Net Margin
-9.4%
▲ +1562bp YoY
ROE
-3.2%
▲ +631bp YoY
Total Assets
$2.1B
▲ +0.8% YoY
EPS (Diluted)
$-1.22
▲ +60.5% YoY
Operating Cash Flow
$72M
▲ +43.5% YoY
Source: XBRL data from Azenta, Inc. FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on Azenta, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.